Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.1 (
chymotrypsin
)
10,938
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Treatment of purified
tryptophanyl-tRNA synthetase
with either
chymotrypsin
, papain, subtilisin or elastase converts all the enzyme into a high-molecular-weight intermediate. This protease-resistant core molecule has the same dimeric structure as the native protein and possesses the ability to bind substrates (tryptophan, ATP and tRNATrp) but is catalytically inactive. The monomer molecular weight of the protease-treated enzyme is 39000 compared to 54000 for the intact molecule. Chemical studies indicate that proteases excise the amino-terminal part of the polypeptide chain. It has been demonstrated previously that removal of a 13000-dalton fragment from the amino-terminal region of the
tryptophanyl-tRNA synthetase
converts the native enzyme to another active form. Cleavage of 20 additional amino acids produces the inactive protease-resistant core.
...
PMID:Limited proteolysis of tryptophanyl-tRNA synthetase from beef pancreas. 124 79
